With your summary jazzapat you suggest that antibiotics is part...

First 19 Last

Share
Profile

Follow
chrisnj

998 Posts.

12

15/03/19

12:01

Post #: 37773218
Share

Originally posted by jazzapat: ↑

hi Chris, I don’t think the antibiotic dosing for the second phase III trial is the issue. This trial design was agreed with the FDA and supports the claim for the prevention of recurrent BV. E.g. the antibiotics treated the BV and vivagel prevented recurance in a population who suffered from rBV. Primary and secondary points all met. This supports the claim for prevention after treatment.

data from the first phase III trial was largely used (in my opinion) to support the BV treatment claim. This is the trial that initially missed the primary end points at TOC but was statistically signicant at EOT. SPL subsequently indicated that it had passed the primary end points at revised TOC, but I do not recall seeing detailed data on Testing of Cure for these revised / shortened time periods.

Hence, it appears that we can assume vivagel
- prevents recurance of rBV after it has been treated with antiobiotics
- treats bv up until end of treatment / whilst it is being applied
- but that BV returns after around 3 weeks after treatment ceases (why we failed the first phase III primary end points).

My view is that we will work with the FDA to get approval of some sort with limited claims but that we will need more data for stronger claims around treatment. There are many products available now for eczema as an example that reduce the symptoms and prevent / delay recurance or provide temporary relief etc. I think we will see a similar outcome here.

The above is is all speculation just like Stockrocks assertion that we will definitely need another clinical trial.

Regardless, SPL needs to focus on preparing as best as possible for this FDA meeting and leveraging as much local FDA expertise they can. They need to launce in other regions ASAP and get more DEP programs into the clinic to stop the share price decline.

Expand

With your summary jazzapat you suggest that antibiotics is part of the treatment regime whereas it has always been claimed by SPL that they are dispensing with the need to use them.

Also l thought the 2nd trial was for both treatment and prevention of recurrence??

SPL Price at posting: $1.00 Sentiment: Hold Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

BTH

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

ME1

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

EDE

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

BNL

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

LYN

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

AN1

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

AUN

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

GRL

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

There are more pages in this discussion • 3 more messages in this thread...

First 19 Last

Add SPL (ASX) to my watchlist

(20min delay)
Last 10.5¢		Change 0.000(0.00%)		Mkt cap ! $43.82M

Open	High	Low	Value	Volume
10.5¢	11.5¢	10.0¢	$110.6K	1.006M

Buyers (Bids)

No.	Vol.	Price($)
1	83046	10.5¢

Sellers (Offers)

Price($)	Vol.	No.
11.0¢	30000	1

View Market Depth

No.	Vol.	Price($)
1	6000	0.955
4	25073	0.950
1	3925	0.945
3	8847	0.940
1	10000	0.935

Price($)	Vol.	No.
0.960	4540	2
0.965	15000	1
0.970	13906	2
0.975	10000	1
0.980	19012	1

Last trade - 16.10pm 15/11/2024 (20 minute delay)

SPL (ASX) Chart

With your summary jazzapat you suggest that antibiotics is part...

Top Stories

Bigtincan's Board backs Investcorp offer: Why a NASDAQ listing could be game-changing

Banshee's historic trenches prove rich in antimony and gold for GDM

Week 46 Wrap: Copper hits 2mth low as Trump threatens net zero pace; US rally fades; HotCopper’s picks

NT Gov't delivers environmental approval for Empire Energy's Beetaloo Carpentaria pilot gas play

Blue Star Helium sees approval for five more wells at 'Galactica/Pegasus' project in Colorado

InhaleRX gains approval for clinical trial to test non-opioid therapy for cancer pain

CuFe sells its Crossroads gold royalty to Northern Star for $4M cash; says better than waiting for mine launch

Cyclone signs MOU with Vale for development of Iron Bear play

HotCopper Highlights: Your most watched stocks for Week 46, 2024

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Buyers (Bids)

Sellers (Offers)